IRCT201310164113N4已完成未知
Evaluation of Enteral Recombinant Erythropoietin(R-EPO) in prevention of Necrotizing Entrocolits in Very Low Birth Weight infants
Pediatric Health Research Center of Tabriz University of Medical Sceinces0 个研究点目标入组 105 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 105
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- no limit 至 1 year（—）
- 性别
- All
入选标准
- •Patients will eligible if they are inborn preterm infants with gestational age of 28 weeks or less or Birth weight 1250 gram or less and they are Appropriate for Gestational Age. Patients will consider ineligible if they have any congenital anomaly of the gastrointestinal tract (i.e., omphalocele, gastroschisis, tracheoesophageal fistula, intestinal perforation), or have other major congenital anomalies (congenital heart disease, neural tube defect, congenital diaphragmatic hernia, Trisomy, etc.).They Also will exclude if the neonates judge as being too ill to be acceptable study candidates; this criterion will set as receiving mechanical ventilation with an FIO2>0.60
排除标准
- 未提供
研究者
相似试验
已完成
1 期
The benefits of Erythropoietin in reducing the need for blood transfusions in patients receiving chemotherapysolid insitu tumor of the body.In situ neoplasmsD00-D09IRCT2015061822805N1Vice Chancellor for research of Tabriz University of Medical Sciences60
已完成
4 期
Impact of Recombinant Human Erythropoietin (ior EPO-CIM) in oncology pediatric patients with post chemo and /or radiotherapy.Anemia secondary to chemo and/or radiotherapy.RPCEC00000080Center of Molecular Immunology(CIM)161
已完成
不适用
evaluation the effect of erythropoitin on multiple trauma patients that need blood transfusioblood transfusion in multiple trauma patient.Traumatic secondary and recurrent haemorrhageIRCT2014100617891N4Vice Chancellor for Research60
已完成
4 期
Impact of Human Recombinant Erithoropoietin (ior EPOCIM) in cancer patients with post Chemo and Radiotherapy induced anemia.Anemia secondary to chemo and/or radiotherapy.RPCEC00000079Center of Molecular Immunology(CIM)338
已完成
不适用
Recombinant human erythropoietin therapy in critically ill patients: a dose response studyCritically ill patients with anaemiaHaematological DisordersAnaemiaISRCTN48523317Janssen-Cilag (Greece)148